NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
29 trialsNCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04316117 2026-03-23
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03941730 2026-03-05
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT06860815 2026-01-28
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting
NCT05226663 2025-12-15
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06518057 2025-12-11
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
Phase 2 Recruiting
NCT06910761 2025-12-08
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT02849496 2025-11-24
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02827877 2025-11-14
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04529044 2025-10-30
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT06260033 2025-10-06
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06525766 2025-10-03
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT02498613 2025-09-25
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01149083 2025-08-15
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01937117 2025-07-01
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT00123799 2024-06-21
Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection
AHS Cancer Control Alberta
Phase 2 Terminated
NCT00618657 2024-02-28
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
Phase 2 Completed
NCT03065712 2020-05-12
Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT00602043 2020-02-19
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00771381 2019-08-22
A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer
AHS Cancer Control Alberta
Phase 2 Terminated
NCT00379197 2017-12-28
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00572728 2016-12-30
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00043017 2013-10-09
ACRIN 6657
American College of Radiology Imaging Network
Phase 2 Completed
NCT00978770 2013-08-07
MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00233974 2012-03-07
Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00107484 2010-05-03
Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer
Virginia Commonwealth University
Phase 2 Completed